Clinical trial · Interventional
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer
NCT00750178CI-TRIAL-00026848completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0683 in patients with advanced cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Advanced | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| vorinostat (MK0683 ) | Drug | Vorinostat | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A
- description
- MK0683
- interventionNames
- Drug: vorinostat (MK0683 )
Primary outcomes (1)
- measure
- Safety, tolerability, and PK of MK0683
- timeFrame
- 28 Days
Secondary outcomes (1)
- measure
- Urinary excretion of MK0683
- timeFrame
- 28 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years or older * Must agree to consume high fat meal and agree to fasting conditions * Limit alcohol consumption Exclusion Criteria: * Patient has a history of drug or alcohol abuse within 5 years of start of study * Patient is known to have HIV * Patient has participated in another investigational study within 4 weeks of start of study * Patient cannot stop taking certain medications or herbal remedies * Patient will require immunologic, radiation, surgery, or chemotherapy during the study * Patient requires frequent blood transfusions * Female patient is pregnant or nursing * Patient has an active Hepatitis B or C infection
References
Publications (1)
- RESULTRubin EH, Agrawal NG, Friedman EJ, Scott P, Mazina KE, Sun L, Du L, Ricker JL, Frankel SR, Gottesdiener KM, Wagner JA, Iwamoto M. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res. 2006 Dec 1;12(23):7039-45. doi: 10.1158/1078-0432.CCR-06-1802. PMID 17145826